Residual disease in chronic myeloid leukemia after induction of molecular remission [7]

New England Journal of Medicine

Volumn 349, Issue 15, 2003, Pages 1483-1484

  Lange, Thoralf ^a   Niederwieser, Dietger W ^a   Deininger, Michael W N ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB;

CANCER REGRESSION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; PATIENT MONITORING; PRIORITY JOURNAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY;

EID: 0141863481     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200310093491521     Document Type: Letter

References (5)

1. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-36.
2. Guo JQ, Lin H, Kantarjian H, et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002;16: 2447-53.
3. Hughes T, Kaeda J, Branford S, et al. Molecular responses to imatinib (ST1571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study. Blood 2002;100:93a. abstract.
4. Barbany G, Höglund M, Simonsson B. Complete remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 2002;347:539-40.
5. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-7.